CorVel Corp

Análisis de la acción CorVel Corp (CRVL)

$83.880

+3.296 (+3.93%)Al cierre

Loading chart…
Máximo
84.155
Apertura
81.400
Precio medio ponderado por volumen
83.14
Volumen
142.85K
Capitalización
4.32B
Mínimo
81.390
Importe
11.88M
EV/EBITDA, TTM
0.00

CorVel Corporation applies technology, including artificial intelligence, machine learning and natural language processing, to enhance the management of episodes of care and the related health-care costs. The Company partners with employers, third-party administrators, insurance companies and government agencies to assist its customers in managing the medical costs of workers compensation, group health and auto insurance, and in monitoring the quality of care provided to claimants. Its services include claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care and Medicare services. It delivers its solutions in three ways - as a fully integrated claims-management program, as discrete standalone services, or as targeted add-ons that enhance an existing client workflow. Integrated, end-to-end bundled programs are designed primarily for buyers such as self-insured employers who want a single, turnkey partner.

www.corvel.com

Análisis de IA of CorVel Corp (CRVL)

Comprar

CorVel Corp is a good buy right now due to its recent strong financial performance, with a Q1 net profit of $32.22 million and an EPS of $0.63, both showing significant year-over-year growth. Additionally, the RSI is at 77.48, indicating strong momentum, while the stock has shown a 21.22% year-to-date increase, reflecting positive market sentiment. The main risk is the high forward P/E of 23.75, suggesting that the stock may be overvalued if growth expectations are not met.

Métricas de valoración

El PER previsto actual de CorVel Corp (CRVL) es 23.75, frente a su media de 5 años de 90.96.

PER previsto

Infravalorado
Media 5A P/E
90.96
P/E actual
23.75
Sobrevalorada
130.81
Infravalorada
51.10

EV/EBITDA previsto

Muy infravalorado
Media 5A EV/EBITDA
0.00
EV/EBITDA actual
0.00
Sobrevalorada
0.00
Infravalorada
0.00

Precio/ventas previsto

Muy infravalorado
Media 5A P/S
7.02
P/S actual
0.00
Sobrevalorada
8.94
Infravalorada
5.10

Ballenas con CRVL en cartera

K

Kayne Anderson Rudnick Investment Management, LLC

+ Con en carteraCRVL

-1.79%

Rentabilidad a 3 meses

Cronología de eventos

2026-06-01 (ET)

16:40:00

CorVel Appoints Sarah Scott as CEO

2026-05-20 (ET)

06:20:00

Q4 Revenue Reaches $248.54M

2026-02-03 (ET)

06:20:00

Q3 Revenue Reaches $236M vs. $228M Last Year

2025-02-13 (ET)

06:36:59

CorVel appoints Scott as Executive Vice President of Product

2024-12-24 (ET)

12:16:10

CorVel announces effectiveness of three-for-one forward stock split

Noticias

Preguntas frecuentes sobre CRVL, respondidas por Alphio AI

CorVel Corporation applies technology, including artificial intelligence, machine learning and natural language processing, to enhance the management of episodes of care and the related health-care costs. The Company partners with employers, third-party administrators, insurance companies and government agencies to assist its customers in managing the medical costs of workers compensation, group health and auto insurance, and in monitoring the quality of care provided to claimants. Its services include claims management, bill review, preferred provider networks, utilization management, case management, pharmacy services, directed care and Medicare services. It delivers its solutions in three ways - as a fully integrated claims-management program, as discrete standalone services, or as targeted add-ons that enhance an existing client workflow. Integrated, end-to-end bundled programs are designed primarily for buyers such as self-insured employers who want a single, turnkey partner. It operates in the Healthcare sector (INSURANCE AGENTS, BROKERS & SERVICE industry).

CorVel Corp is a good buy right now due to its recent strong financial performance, with a Q1 net profit of $32.22 million and an EPS of $0.63, both showing significant year-over-year growth. Additionally, the RSI is at 77.48, indicating strong momentum, while the stock has shown a 21.22% year-to-date increase, reflecting positive market sentiment. The main risk is the high forward P/E of 23.75, suggesting that the stock may be overvalued if growth expectations are not met.

Comunidad

Más ↗

Aún no hay publicaciones

Regístrate o inicia sesión para participar

Esta página es solo para investigación y no constituye asesoramiento de inversión. Los modelos pueden equivocarse. El rendimiento pasado no garantiza resultados futuros.

Empezar a operar